Showing 241 - 260 results of 75,410 for search '(( a non decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 0.94s Refine Results
  1. 241
  2. 242
  3. 243
  4. 244
  5. 245

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”
  6. 246
  7. 247
  8. 248

    Non-Steady-State Fickian Diffusion Models Decrease the Estimated Gel Layer Diffusion Coefficient Uncertainty for Diffusive Gradients in Thin-Films Passive Samplers by Samuel D. Hodges (16412358)

    Published 2023
    “…A finite difference model (FDM) developed based on Fick’s second law with non-steady-state (N-SS) flux decreased uncertainty in <i>D</i><sub>Gel</sub> tenfold. …”
  9. 249
  10. 250

    Data_Sheet_1_Improved body composition decreases the fat content in non-alcoholic fatty liver disease, a meta-analysis and systematic review of longitudinal studies.docx by Dóra Mátis (15407060)

    Published 2023
    “…Background<p>Based on cross-sectional studies, there is a link between body composition parameters and steatosis in non-alcoholic fatty liver disease (NAFLD). …”
  11. 251
  12. 252
  13. 253
  14. 254

    HERVK HML-2 <i>env</i> knockdown decreases IFN-I expression and alters the secretory profile of THP1 monocytes and primary MDMs. by Natallia Mikhalkevich (10113822)

    Published 2021
    “…Green dots represent significant (above blue line) or non-significant decrease in expression of indicated genes in shRNA-Env vs. control shRNA expressing cells (<i>p</i><0.05, fold change >2.0). …”
  15. 255
  16. 256
  17. 257

    GSK343 decreased neuroblastoma viability, proliferation, and motility. by Laura V. Bownes (10276762)

    Published 2021
    “…<p>(A) SK-N-AS, SK-N-BE(2), SH-EP and WAC(2) cells (1.5 × 10<sup>3</sup> cells) were treated with increasing concentrations of GSK343 (0, 5, 15, 25 μM) for 24 hours and viability was measured using alamarBlue<sup>®</sup> assay. …”
  18. 258
  19. 259
  20. 260